A Retrospective Analysis in a Real World Database of Different Drug Categories Gap Between First Prescription and Dispensation in Primary Care in France
Author(s)
ABSTRACT WITHDRAWN
OBJECTIVES: The study aims to describe the gap between the first prescription and the time of dispensing of different medications in chronic and acute pathologies in primary care in France.
METHODS: Patients from the primary care database THIN® France were included according criteria: at least one consultation in 2023, 12 months of history prior 2023, one reimbursement in 2022 and in 2023 and 12 months between reimbursement information between the 2 years. For chronic disease, (antihypertensives (C02), anxiolytics (N05B), bisphosphonates (M05BA), hypnotics and sedatives (N05CD), glucocorticoids (R03BA), Lipid modifying agents (C10), antiparkinson drugs (N04), adrenergics in combination excl. anticholinergics (R03AK), we selected the first prescription after 2014; and for acute disease or prevention (antibiotics (J01), paxlovid (J05AE30), pertussis vaccines, (J07AJ, J07AJ01/02/51, J07AC02/05/06/09/11/12/13) and salbutamol (R03AC02)), the first prescription in 2023. We have studied the dispensations during the 90 days after the first prescription.
RESULTS: Gap between dispensation were (mean in days, number of patients, proportion of patients with a gap lower than 3 days and between the third and 14th day were: antihypertensives (9, 6.584, 17,15%, 71,95%), anxiolytics (7, 104.357, 17,79%, 74,04%), bisphosphonates (12, 4.734, 11,85%, 69,46%), hypnotics and sedatives (7, 36.387, 17,26%, 74,80%), glucocorticoids (5 , 48.222 , 21,22%, 75,49%), Lipid modifying agents (11, 49.056, 14,40%, 71,00%), antiparkinson drugs (11, 4.740, 15,13%, 71,48%), adrenergics in combination excl. anticholinergics (5, 63.241, 20,11%, 75,57%), antibiotics (5, 184.605, 21,76%, 74,83%), paxlovid (4, 1.336, 20,36%, 78,67%), pertussis vaccines (15, 19.057, 11,38%, 60,74%) and salbutamol (8, 38.601, 17,61%, 71,85%).
CONCLUSIONS: Time between prescription and dispensing of a treatment varies widely, depending on the type of disease and the category of drug. This is of vital importance for real-life pharmacological studies, as well as pharmacovigilance studies.
Conference/Value in Health Info
Code
PCR204
Topic
Patient-Centered Research
Topic Subcategory
Adherence, Persistence, & Compliance
Disease
Cardiovascular Disorders (including MI, Stroke, Circulatory), Infectious Disease (non-vaccine), Mental Health (including addition), Neurological Disorders, Respiratory-Related Disorders (Allergy, Asthma, Smoking, Other Respiratory)